Indications

GLIADEL® Wafer (polifeprosan 20 with carmustine implant) is indicated in patients with newly diagnosed high-grade malignant glioma as an adjunct to surgery and radiation.

GLIADEL Wafer is also indicated in patients with recurrent glioblastoma multiforme as an adjunct to surgery.

Important Safety Information

You should not be given GLIADEL Wafer if you are allergic to carmustine or any of the components of GLIADEL Wafer. If you are undergoing surgery for malignant glioma and implantation of GLIADEL Wafer, you should be monitored closely for known complications, including convulsions, infections, abnormal wound healing, and swelling of the brain. If you are pregnant or are planning to become pregnant, you should understand that carmustine, the active component of GLIADEL Wafer, can cause harm to the fetus if given to a pregnant woman. It is not known if either carmustine, or other components of GLIADEL Wafer are excreted in human milk. Please see additional Important Safety Information below.

For US Audiences Only

This Web site contains information relating to various medical conditions and treatment. Such information is provided for educational purposes only and is not meant to be a substitute for the advice of a physician or other health care professionals. You should not use this information for diagnosing a health problem or disease. In order for you to make intelligent health care decisions, you should always consult with a physician or other health care provider for you, or your loved ones, personal medical needs. Individual responses to treatment may vary.

This site is intended for residents of the United States only. Laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. This site contains information about products that may have different product labeling in different countries. This site is published by Eisai Inc. which is solely responsible for its contents.